Trial
NCT02393248
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Incyte Corporation
Collaborators
—
Condition
Lung Cancer
Intervention
Pemigatinib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-01-06